



ASIP News



The Arab Society for Intellectual Property (ASIP)

The Arab Society for Intellectual Property (ASIP) headed by Dr. Talal Abu-Ghazaleh is a non-profit organization that was established on February 23, 1987 in Munich Germany, by some of the top practitioners in the many fields of intellectual property (IP) in the Arab region. Its mission is to bring together the IP professionals and practitioners in the Arab region and to help build awareness and understanding of intellectual property issues and their dynamics.

In this Issue

- » AGIP staff in Jordan pass ACIPP exam
- » ASIP organizes a comprehensive training course on arbitration
- » Staurus announces issuance of US Patent for immunoglobulins and variants directed against pathogenic microbes
- » European Patent grants for IMP731 antibody

AGIP staff in Jordan pass ACIPP exam

AMMAN – August 25, 2016 Abu-Ghazaleh Intellectual Property (AGIP) announced that some of its staff in Amman Office have successfully passed the exams of the “Arab Certified Intellectual Property Practitioner/ACIPP” program.

Accordingly, participants have been granted the ACIPP Certificate issued by the Arab Society for Intellectual Property (ASIP).

ACIPP Program covers the following IP disciplines:

- Trademarks and unfair competition.
- Patents of inventions and trade secrets.
- Copyright and related rights.



ASIP organizes a comprehensive training course on arbitration

Amman – September 1, 2016 ASIP will hold a comprehensive training course on arbitration early October 2016 which includes the following modules:

1. Arbitration in IP Disputes
2. Arbitration in Construction Contracts
3. The Art of Arbitration and Arbitrator’s Skills
4. Arbitrator Qualifying and Preparing Program


The main goals of this training course:

1. Introduce the right methods of resolving disputes arising between parties to contracts, find alternative methods of construction contract dispute resolution.
2. Learn the skills of drafting construction contracts, notices, and arbitration agreements
3. Provide trainees with the basic skills of arbitration, knowledge on alternative methods.
4. Provide trainees with the arbitration techniques and process, which makes it easier for them to resolve disputes
5. Contribute in legally preparing and qualifying arbitrators, define arbitration and the basics of arbitration, and disseminate the culture of arbitration



Staurus announces issuance of US Patent for immunoglobulins and variants directed against pathogenic microbes

CALIFORNIA – August 30, 2016 Staurus Pharma LLC, announced that the United States Patent and Trademark Office has granted a key patent covering the composition of novel Fc variant antibodies for the treatment for *Staphylococcus aureus* (*S.aureus*) infections. The immunoglobulins of the claimed Fc variants prevent bacterial virulence factors from neutralizing the effector function of anti-*S. aureus* therapeutic antibodies. Such Fc modifications can be applied to any existing anti-*S.aureus* therapeutic monoclonal antibody to improve efficacy.



This newly allowed patent covers proprietary Immunoglobulin Fc modifications, which should significantly expand anti-*S.aureus* therapeutic opportunities beyond traditional antibiotics. Because mAbs do not bind to the same bacterial targets as antibiotics, this new therapeutic approach could be particularly useful in the treatment of antibiotic resistant infections. They may also complement antibiotics in the management of immunocompromised patients. In addition, mAbs have significantly longer half-lives, providing compliance advantages (single dose) and less toxicity to the normal body flora.

“At Staurus, we have dedicated ourselves to understanding why host anti-*S.aureus* antibodies are not able to effectively protect patients from life threatening complications following *S.aureus* infections. Circumventing microbial immune evasion through engineering Fc variant antibodies that do not bind to *S.aureus* Fc Binding Proteins (FcBPs) is central to this novel approach. Having an issued U.S. patent is a critical step in the development of this important antibody-based therapeutic approach,” said Nick Lydon, Co-founder of Staurus Pharma LLC. “The issued patent will protect this novel Fc variant antibody technology and allow Staurus to work with a number of collaborators to select the best anti-*S.aureus* antibody candidates for further development.”

U.S. Patent No. 9,416,171 B2, entitled “Immunoglobulins and variants directed against pathogenic microbes,” provides commercial rights in the United States through March 2036.

Source: <http://blog.ip.com/2016/08/staurus-announces-issuance-of-u-s-patent-for-immunoglobulins-and-variants-directed-against-pathogenic-microbes/>

European Patent grants for IMP731 antibody



SYDNEY- August 26, 2016 Prima BioMed (ASX: PRR; NASDAQ: PBMD) announces the granting of patent number 2142210 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the European Patent Office.

The patent relates to Prima’s IMP731 antibody, originally developed by Immuteq SAS. The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent cytotoxicity and antibody-dependent cell cytotoxicity.

Rights for the development of the IMP731 antibody were granted in December 2010 to GSK, which has commenced first-in-human clinical trials of the proprietary antibody.

Source: <http://blog.ip.com/2016/08/european-patent-grants-for-imp731-antibody/>